Two types of combined progestogen-oestrogen oral contraceptives were administered to twelve subjects each over five consecutive cycles. Coagulation status was assessed in one control cycle before starting medication and in the first, third and fifth cycles during administration. The tests used included platelet counts and adhesiveness, clotting and recalcification time, prothrombin time, fibrinogen levels and euglobulin lysis times.